Showing results (241-250 of 317) with videos related to

Sort By:
Pageof 32
Plos One|June 16, 2022
Metagenomic shotgun sequencing of blood to identify bacteria and viruses in leukemic febrile neutropeniaPrakhar Vijayvargiya, Adeline Feri, Mathilde Mairey, et al.
Blood Cancer Journal|March 3, 2021
Mayo Clinic experience with 1123 adults with acute myeloid leukemiaKebede H Begna, Walid Ali, Naseema Gangat, et al.
American Journal of Clinical Pathology|May 12, 2021
Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 MutationsElise R Venable, Dong Chen, Constance P Chen, et al.
Rheumatology (Oxford, England)|August 26, 2024
Acute kidney injury, an underrecognized feature of VEXAS syndromeKambiz Kalantari, Megan M Sullivan, Loren P Herrera Hernandez, et al.
Bone Marrow Transplantation|April 23, 2013
Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral centerA Dispenzieri, K Seenithamby, M Q Lacy, et al.
Mayo Clinic Proceedings|September 7, 2021
Clinical Heterogeneity of the VEXAS Syndrome: A Case SeriesMatthew J Koster, Taxiarchis Kourelis, Kaaren K Reichard, et al.
Blood|August 5, 2016
A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemiaDaniel A Lichtenstein, Andrew W Crispin, Anoop K Sendamarai, et al.
American Journal of Hematology|September 3, 2025
Triple A Plus (AAA+) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 PatientsAyalew Tefferi, Giuseppe G Loscocco, Lior Rokach, et al.
American Journal of Hematology|February 18, 2026
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating AgentNaseema Gangat, Momna Warraich, Sudhesh Kumar, et al.
American Journal of Hematology|January 28, 2025
TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic RelevanceAyalew Tefferi, Maymona Abdelmagid, Giuseppe G Loscocco, et al.
Pageof 32